Follows adults with kidney disease to study bone and heart health
Observes calcium and phosphate levels, bone and heart disease in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: The CPH-MBD Cohort
Key facts
- Where
- Herlev, DenmarkSee the site
Where in Denmark
- Department of Nephrology, outpatient clinic, Herlev HospitalHerlev, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Herlev Hospital
- Trial code
- NCT07193056
- Record updated
- 16 September 2026
- Original description
Persons with chronic kidney disease (CKD) have a 3-fold increased risk of bone fracture and a 10-fold increased risk of cardiovascular disease than the general population. These increased risks are related to the disturbances in the mineral metabolism, and this clinical entity is termed Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD).Read full original descriptionShow less
Chronic Kidney Disease -Mineral and Bone Disorder, The CPH-MBD Cohort
Persons with chronic kidney disease (CKD) have a 3-fold increased risk of bone fracture and a 10-fold increased risk of cardiovascular disease than the general population. These increased risks are related to the disturbances in the mineral metabolism, and this clinical entity is termed Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD).
The overall aim of the present project is to explore factors that may predict or associate with the development of bone and cardiovascular disease in patients with CKD and hopefully provide insight into underlying mechanisms and pathophysiological pathways for future treatment and prevention.
In a sub study investigators aim to explore the calcium and phosphate balance in patients with CKD and describe how these associate with each other as well as with kidney function (eGFR).
Inclusion: Age ≥18 years; CKD stage 4-5nonD (eGFR ≤ 29 ml/min) according to KDIGO (Kidney Disease Improving Global Outcome) definition.
Exclusion: None.